The Hospital Universitario Rey Juan Carlos is a general hospital in Móstoles, Spain, part of the Servicio Madrileño de Salud network. Inaugurated on 21 March 2012, it is the second hospital in the municipality of Móstoles, after the Hospital Universitario de Móstoles.

During the past decade, Hospital Universitario Rey Juan Carlos conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 7 clinical trials were completed, i.e. on average, 19.4% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 6 clinical trials were completed. i.e. 37.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Universitario Rey Juan Carlos" #1 sponsor was "Grupo Español de Rehabilitación Multimodal" with 3 trials, followed by "Pfizer" with 3 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Grupo de Investigación Clínica en Oncología Radioterapia" with 2 trials sponsored and "Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz" with 2 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitario Rey Juan Carlos" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator, "Spanish Society of Cardiology" with 2 trials as a collaborator, "Adknoma" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 32 different institutions and companies that were collaborators in the rest 42 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Universitario Rey Juan Carlos" are "Perioperative Care" (3 trials), "Postoperative Complications" (3 trials), "Atopic Dermatitis" (2 trials), "Atrial Fibrillation" (2 trials) and "COVID-19" (2 trials). Many other conditions were trialed in "Hospital Universitario Rey Juan Carlos" in a lesser frequency.

Most popular intervention types in "Hospital Universitario Rey Juan Carlos" are "Drug" (21 trials), "Other" (4 trials), "Device" (3 trials), "Procedure" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Baricitinib" (2 trials), "Bortezomib" (2 trials), "Dexamethasone" (2 trials) and "10,000 MG01 + 10,000 T517" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Universitario Rey Juan Carlos" are 34 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Hospital Universitario Rey Juan Carlos". 1 are not yet recruiting, 8 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Hospital Universitario Rey Juan Carlos, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Universitario Rey Juan Carlos, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 6 trials that are defined as “Not Applicable".